SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in December:
7th Annual Evercore HealthCONx Conference
Tuesday, December 3, 2024, at 10:00 a.m. ET
Citi 2024 Global Healthcare Conference
Wednesday, December 4, 2024, at 2:30 p.m. ET
Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations, and replays will be available for up to 30 days following each event.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit www.travere.com.
Contact:
| Last Trade: | US$25.16 |
| Daily Change: | -0.91 -3.49 |
| Daily Volume: | 1,565,379 |
| Market Cap: | US$2.240B |
September 10, 2025 September 03, 2025 August 27, 2025 June 03, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
